share_log

Brookline Capital Downgrades Dare Bioscience to Hold

Benzinga ·  Apr 18 01:28

Brookline Capital analyst Kemp Dolliver downgrades Dare Bioscience (NASDAQ:DARE) from Buy to Hold.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment